Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that its Chief Executive Officer, Maria Maccecchini, Ph.D., will present at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on February …
Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has announced the completion this week of its underwritten public offering, generating $21 million in gross proceeds. The offering consisted of 5,250,000 shares …
Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has revealed plans to conduct an underwritten public offering of common stock and warrants. The company will sell all offered securities directly, with …
Annovis Bio Announces Public Offering of Common Stock and Warrants Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been granted a U.S. patent for the use of its leading compound, buntanetap, in the treatment and prevention of acute brain and …
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an updated protocol for the company’s pivotal Phase 3 Alzheimer’s (AD) …
FDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s Study Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has scheduled a live investor webcast for December 11, 2024, at 4:30 PM EST. The event will feature critical updates on the …
Annovis Bio Announces Investor Webcast to Share Key Updates Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside significant progress in its Alzheimer’s treatment pipeline.
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson’s role will be pivotal in ensuring the medical, …
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced a successful outcome from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The FDA has given …
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials Read More